What Is TRZ (10 Vials)?
Type Dual GIP and GLP-1 Receptor Agonist CAS Number 2023788-19-2 Molecular Weight 4813.5 g/mol Molecular Weight (Cu) N/A Amino Acids 39 Amino Acids Sequence Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20-fatty-diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Stability Information
High-purity dual-agonist peptideSensitive to light, heat, and moistureStrictly for professional laboratory use Lyophilized (powder) -20°C · up to 2 years Reconstituted 2-8°C · up to 30 days
About TRZ (10 Vials)
TRZ is a synthetic peptide researched for its unique ability to act as a dual agonist for the Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. Supplied in a 10-vial pack as a stable lyophilized powder, it is a primary subject of study in fat metabolism and weight management research. This compound provides a consistent reagent for investigating how the activation of multiple incretin pathways can synergistically influence insulin sensitivity and metabolic signaling. It is intended strictly for laboratory research and development purposes by qualified professionals only.
Mechanism of Action
The mechanism involves the simultaneous activation of both GIP and GLP-1 receptors. GLP-1 receptor activation is studied for its ability to slow gastric emptying and suppress appetite signaling in the brain. GIP receptor activation is researched for its role in improving insulin sensitivity and regulating lipid metabolism in adipose tissue. In research assays, this dual-action “twincretin” approach is investigated for its potential to optimize metabolic homeostasis more effectively than single-receptor agonists.
What Research Has Shown
Metabolic Research 99 Purity Percentage (HPLC Verified) Dual Incretin Signaling Efficiency TRZ Dual Agonist 95.5% Trial details: Investigative studies focusing on the synergistic effects of GIP and GLP-1 receptor activation on glucose-dependent insulin secretion and energy homeostasis in experimental models. Bioenergetic Results
Multi-Pathway Metabolic Homeostasis
Findings from GIP and GLP-1 receptor studies
97% Insulin Sensitivity Enhanced Glucose Metabolism Note: Results highlight the compound’s ability to act as a potent dual-system metabolic regulator.
Research Highlights
Dual Incretin Synergism
Research focusing on the combined binding dynamics and signaling of GIP and GLP-1 receptors.
Pancreatic Beta-Cell Signaling
Investigating the enhancement of glucose-dependent insulin secretion in metabolic models.
Adipose Tissue Metabolism
Studies exploring how dual agonism influences lipid storage and breakdown in adipose cells.
Energy Balance Homeostasis
Exploration of how dual agonists influence satiety signaling and resting energy expenditure.
Product Specifications
- Molecular Formula
- C₆₂H₉₈N₁₆O₂₂
- Molecular Weight
- 1419.53 g/mol
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Purity
- ≥99% (HPLC verified)
- Form
- Lyophilized powder
- Appearance
- White to off-white powder
- Solubility
- Soluble in water, bacteriostatic water
- Storage
- -20°C (lyophilized), 2-8°C (reconstituted)
Research Studies
TRZ: A Dual Agonist for Metabolic Homeostasis
A comprehensive analysis of dual incretin signaling and its impact on glycemic regulation and energy expenditure.
Frias J.P. & Nauck M.A. View Full Study
Frequently Asked Questions
What is a dual agonist in the context of TRZ?
It means the compound targets two different receptors simultaneously: the Glucose-dependent Insulinotropic Polypeptide (GIP) and the Glucagon-Like Peptide-1 (GLP-1) receptors.
Is this product FDA evaluated?
No, these products are intended strictly for laboratory research and have not been evaluated or approved by the FDA for human use.
Frequently bought together: Selank, 5-amino-mq, Tesamorelin
Related products
